Prior Auth Required
10253 - phase 3 trial. Lancet. 2020 Sep 12;396( ):759-769. doi: 10.1016/ -6736(20) -X. Epub
This procedure appears on the selected insurer prior authorization source.
Prior authorizationPrior Auth Required
Procedure / Servicephase 3 trial. Lancet. 2020 Sep 12;396( ):759-769. doi: 10.1016/ -6736(20) -X. Epub
Procedure / Service Description
Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. - 2 Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive 9/2020 6/2023 hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Erratum in: Lancet. 2020 Sep 12;396(10253):758. PMID: 32871100. 3 CamzyosTM (mavacamten) [prescribing information]. Brisbane, CA: MyoKardia, Inc. (Bristol Myers 4/2024 3/2025
Likely documents
- Confirm benefit details
- Submit clinical notes if requested by the plan
Next actions
- Confirm the current plan policy before submission.
- Use the insurer authorization workflow for this listed code.